Log in to search using one of your social media accounts:

 

HLA-mismatched Microtransplant Benefits Older AML Patients HLA-mismatched Microtransplant Benefits Older AML Patients
Most older patients with newly diagnosed acute myeloid leukemia (AML) achieve complete remission and good overall survival after HLA-mismatched microtransplant, according to results from 12 centers in China, the United States, and Spain.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

How to manage family life when your child has cancer
Valerie, with husband Doron, son Evan and daughter Ruby When our daughter, Ruby, was diagnosed with acute lymphoblastic leukemia (ALL) at one and a half years old, my husband and I were immediately transformed from working parents with two young children, to parental caregivers for a child with cancer. Between hospital stays, medications and appointments, there was so much to keep track of. It can be overwhelming at times, but there are ways to manage life after your child is diagnosed with cancer. Settle into to this new normal. It can be easy to stay in crisis mode when something like a cancer diagnosis interrupts y...
Source: Thrive, Children's Hospital Boston - September 20, 2017 Category: Pediatrics Authors: Valerie Graf Tags: Diseases & Conditions Parenting Cancer Dana-Farber/Boston Children's Cancer and Blood Disorders Center Source Type: news

Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10 percent of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

GATA1 as a Marker for Erythroid and Megakaryocytic Lineages GATA1 as a Marker for Erythroid and Megakaryocytic Lineages
This study investigated the use of GATA binding factor 1 as a marker for neoplastic cells of pure erythroleukemia and acute megakaryoblastic leukemia.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 14, 2017 Category: American Health Source Type: news

Adult Acute Lymphoblastic Leukemia (ALL)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment
Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Inhibitors support immune therapy for leukemia
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and T ü bingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Mylotarg to treat acute myeloid leukemia
The U.S. Food and Drug Administration approved Mylotarg, or gemtuzumab, for the treatment of adults with newly diagnosed acute myloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 5, 2017 Category: Consumer Health News Source Type: news

Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 3, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia
September 1, 2017 -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 1, 2017 Category: Consumer Health News Source Type: news

Mylotarg Back on Market with New FDA Approval
(MedPage Today) -- Smaller doses OK'd for certain acute myeloid leukemia indications (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 1, 2017 Category: American Health Source Type: news

Mylotarg Approved for AML: Drug Returns to Market Mylotarg Approved for AML: Drug Returns to Market
After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg
FRIDAY, Sept. 1, 2017 -- The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia -- CD33-positive AML. An earlier version of the drug had been withdrawn... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2017 Category: General Medicine Source Type: news

FDA approves Pfizer's leukemia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
SILVER SPRING, Md., Sept. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors expres... Biopharmaceuticals, Oncology, FDA Pfizer, Mylotarg, gemtuzumab ozogamicin, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 1, 2017 Category: American Health Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight Update your membership record today! If you complete the renewal process by Friday, September 8, you can expect to receive your certificate by the end of the month. If you have not yet verified that your organization’s record is up-to-date, check out our Membership renewal flyer for more information. National Preparedness Month begins today! Visit the Ready Campaign web page to learn about this year’s theme, “Disasters Don’t Plan Ahead. You Can” and check out the 2017 promotional toolkit which ...
Source: NN/LM Middle Atlantic Region Blog - September 1, 2017 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

A parent ’s guide to clinical trials
Children with life-threatening conditions, such as cancer, are often candidates for clinical trials. What are they? Which factors should parents weigh in determining whether enrolling in one is a good option for their child? Dr. Steven DuBois, director of the Advancing Childhood Cancer Therapies Clinic at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, answers questions about clinical trials. What are clinical trials? Why are they important? Clinical trials are systematic, scientific investigations of new drugs or therapies for a specific disease. Through clinical trials, we have taken many fatal ped...
Source: Thrive, Children's Hospital Boston - September 1, 2017 Category: Pediatrics Authors: Irene Sege Tags: Ask the Expert Research and Innovation clinical trial Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Steven DuBois Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: World Pharma News)
Source: World Pharma News - September 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis ’ Kymriah receives FDA approval for B-cell precursor ALL treatment
The US Food and Drug Administration (FDA) has approved Novartis ’ Kymriah (tisagenlecleucel) suspension for intravenous infusion to treat patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory or in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Acute myeloid leukemia: Heart drugs may boost chemotherapy
Researchers find that drugs normally used to treat heart and blood vessel disease could also help to improve chemotherapy outcomes for patients with AML. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

FDA Approves Therapy Using Patient ’ s Own Cells To Fight Cancer Cells
BOSTON (CBS) — The Dana Farber Cancer Institute and Boston Children’s Hospital will work to fight cancer in a new way thanks to a new treatment approved by the FDA. CAR-T therapy is for kids and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL). “It’s really an entirely new type of therapy, an entirely new way to fight cancer,” said Dr. Lewis Silverman, the Clinical Director of the Pediatric Hematologic Malignancies Center. Chemotherapy drugs attack dividing cells but are not specific to cancer cells, unlike this new treatment, according to Silverman. “It&...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 31, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Boston Children's Hospital Dana Farber Cancer Institute Juli McDonald Leukemia Source Type: news

First Gene Therapy Approved in U.S. (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA on Wednesday approved tisagenlecleucel (Kymriah) for patients up to age 25 years with B cell precursor acute lymphoblastic leukemia that has relapsed or not responded … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2017 Category: Primary Care Source Type: news

HealthWatch: A New Gene Therapy For Leukemia; A Study On Carbohydrates
This study does not mean you can now eat a ton of butter and steak without worry, but you probably don’t need to feel guilty about eating some fat. In terms of carbohydrates, the study did not distinguish between refined carbs and complex carbs, so further study is needed. (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 30, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Cancer Research Dr. Mallika Marshall Leukemia Source Type: news

FDA Approves Kymriah (tisagenlecleucel) CAR-T Gene Therapy for Acute Lymphoblastic Leukemia
August 30, 2017 -- The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP
The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children ’s Hospital of Philadelphia. The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse. In 2012, Penn and Novartis — a Swiss dr ug company that has its U.S headquarters… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 30, 2017 Category: American Health Authors: John George Source Type: news

FDA OKs 1st Gene Therapy for Use in U.S.
It transforms a patient's immune system cells to fight a form of leukemia Source: HealthDay Related MedlinePlus Pages: Acute Lymphocytic Leukemia, Genes and Gene Therapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 30, 2017 Category: Consumer Health News Source Type: news

First gene therapy coming to U.S. after FDA approval
The U.S. Food and Drug Administration announced today it is making the first gene therapy available in the United States to treat acute lymphoblastic leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 30, 2017 Category: Consumer Health News Source Type: news

FDA approval brings first gene therapy to the United States
The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). (Source: World Pharma News)
Source: World Pharma News - August 30, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA
(University of Chicago Medical Center) The University of Chicago Medicine is one of a limited number of US sites working to offer a breakthrough gene therapy for pediatric acute lymphoblastic leukemia (ALL), which was just approved by the US Food and Drug Administration. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2017 Category: Cancer & Oncology Source Type: news

FDA approves personalized cellular therapy for advanced leukemia developed by University of Pennsylvania and Children's Hospital of Philadelphia
(University of Pennsylvania School of Medicine) In a landmark decision for the field of cancer immunotherapy, the US Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children's Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 30, 2017 Category: Cancer & Oncology Source Type: news

Astellas starts dosing gilteritinib patients in Phase III trial to treat AML
Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news

BESPONSA (inotuzumab ozogamicin) Approved for Treatment of Adult Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia, available for order at Biologics, Inc.
CARY, N.C. (August 22, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected by Pfizer, Inc. to be a specialty pharmacy provider for BESPONSA® (inotuzumab ozogamicin), a promising new IV therapy for adult patients with relapsed o... (Source: McKesson News)
Source: McKesson News - August 22, 2017 Category: Information Technology Source Type: news

Vitamin C injections could play a role in treating blood cancers
Conclusion This mouse study explored whether treatment with vitamin C could restore function of TET2 and therefore block the progression of blood cancers like leukaemia. It found that using high doses of vitamin C intravenously did in fact suppress the growth of leukaemia cancer stem cells in the mice implanted with cell lines from human patients with leukaemia. It also reported that using vitamin C alongside existing treatment with PARP inhibitors helped reduce the progressions of the disease. The researchers suggest that in the future, vitamin C could be used alongside chemotherapy and other conventional treatment forms....
Source: NHS News Feed - August 21, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Pfizer ’s Besponsa gets FDA approval for treatment of B-cell precursor ALL
The US Food and Drug Administration has given approval for Pfizer ’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 20, 2017 Category: Pharmaceuticals Source Type: news

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction in Young Leukemia Patients Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction in Young Leukemia Patients
Arsenic trioxide consolidation allows for use of lower anthracycline doses while preserving excellent survival outcomes in young patients with acute promyelocytic leukemia (APL), according to results from the Children's Oncology Group AAML0631 trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA Approves New Acute Lymphoblastic Leukemia Treatment
The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - August 18, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

New treatment approved for deadly blood cancer
The FDA approved the anti-cancer drug Besponsa, or inotuzumab ozogamicin, to treat B-cell acute lymphoblastic leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 18, 2017 Category: Consumer Health News Source Type: news

FDA Approves New Treatment for Acute Lymphoblastic Leukemia
For patients with relapsed or refractory B - cell ALL who have received one or two prior treatments (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 18, 2017 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)
Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 17, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL FDA Approves Inotuzumab Ozogamicin (Besponsa) for ALL
The new drug is for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). These patients have a very poor prognosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Besponsa (inotuzumab ozogamicin) for Relapsed or Refractory Acute Lymphoblastic Leukemia
August 17, 2017 -- The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). “For adult patients with B-cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 17, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. (Source: World Pharma News)
Source: World Pharma News - August 17, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news